[1] 林凡礼,战义强,贾贡献,等.中国门诊高血压患者血压达标现状及影响因素分析[J].中华高血压杂志,2013,21(2):170-174.
[2] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管杂志,2011,39(7):579-616.
[3] James PA,Oparil S,Carter BL,et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee(JNC8)[J].JAMA,2014,311(5):507-520.
[4] Lindholm LH,Carlberg B,Samuelsson O.Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis[J].Lancet,2005,366(9496):1545-1553.
[5] Bradley HA,Wiysonge CS,Volmink JA,et al.How strong is the evidence for use of beta blockers as first-line therapy for hypertension? Systematic review and meta-analysis[J].J Hypertens,2006,24,(11):2131-2141.
[6] Ma W,Zhang Y.Low rate of resistant hypertension in Chinese patients with hypertension:an analysis of the HOT-CHINA study[J].J Hypertens,2013,31(12):2386-2390.
[7] 廖梅,陈玲.琥珀酸美托洛尔缓释片对高血压患者血压变异性的影响[J].国际医药卫生导报,2012,18(11):1618.
[8] 胡大一,刘力生,余金明,等.中国门诊高血压患者治疗现状登记研究[J].中华心血管病杂志,2010,38(3):230-238.
[9] Brenner R,Waeber B,Allemann Y.Medical treatment of hypertension in Switzerland.The 2009 Swiss Hypertension Survey(SWISSHYPE)[J].Swiss Med Wkly,2011,141(w13169):1-7.
[10] Clement YN,Ali S,Harripaulsingh S,et al.Drug prescribing for hypertension at primary healthcare facilities in Trinidad[J].West Indian Med J,2012,61(1):43-48.
[11] 秦际芳.氯沙坦钾氢氯噻嗪片治疗老年原发性高血压疗效观察[J].慢性病学杂志,2014,15(3):220-221.
[12] 潘华兴,宁观林,林宇彪.氯沙坦钾氢氯噻嗪片治疗老年原发性高血压的研究[J].齐齐哈尔医学院学报,2014,35(8):1128-1129.
[13] 袁静平.缬沙坦/氢氯噻嗪治疗轻中度原发性高血压患者疗效和安全性[J].中国医药导刊,2014,16(2):280-281.
[14] 姜忠梅,李红霞,卢冬喜.氯沙坦钾氢氯噻嗪片治疗高血压合并2型糖尿病的临床研究[J].中国临床医生,2014,42(5):56-57.
[15] 肖玉光,邓伟峰.非洛地平、缬沙坦分别联合氢氯噻嗪治疗老年ISH的疗效及安全性研究[J].重庆医学,2014,43(6):725-728.